Scholars@Duke
Joseph Geradts

Joseph Geradts

Adjunct Professor in the Department of Pathology
Pathology
joseph.geradts@duke.edu
Duke Box 3712, Durham, NC 27710
Rm 3108 Meyer Ward, Department of Pathology, Durham, NC 27710

Overview

Dr. Geradts' primary research focus is on the molecular pathology of breast cancer. His laboratory uses genomic profiling strategies to identify novel candidate breast cancer genes. Dr. Geradts is also interested in biomarker development. He directs the Tissue Core of Duke's Breast Cancer SPORE and collaborates on numerous breast cancer related research projects with other investigators at Duke and elsewhere.

Current Appointments & Affiliations

Adjunct Professor in the Department of Pathology · 2015 - Present Pathology, Clinical Science Departments

In the News

Published December 2, 2013
Duke study: Many breast cancers may be linked with cholesterol byproduct

View All News

Recent Publications

Comparative study of intra- and inter-observer variability in manual scoring of HER2 immunohistochemical stains on glass slides versus paired digital images with emphasis on the low end of the expression spectrum.

Journal Article Hum Pathol · June 25, 2025 With the advent of new therapeutic agents showing efficacy in human breast cancers with low levels of the HER2 oncoprotein, it has become important for pathologists to accurately categorize HER2 expression at the low end of the spectrum. At the same time, ... Full text Link to item Cite

Computational Pathology Detection of Hypoxia-Induced Morphologic Changes in Breast Cancer.

Journal Article Am J Pathol · April 2025 Understanding the tumor hypoxic microenvironment is crucial for grasping tumor biology, clinical progression, and treatment responses. This study presents a novel application of artificial intelligence in computational histopathology to evaluate hypoxia in ... Full text Link to item Cite

XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant.

Journal Article Transl Oncol · May 2024 OBJECTIVE: To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic value and new therapeutic targets in in ... Full text Link to item Cite
View All Publications

Recent Grants

Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy

ResearchCollaborator · Awarded by Department of Defense · 2012 - 2022

A Molecular Framework for Understanding DCIS

ResearchCo Investigator · Awarded by Department of Defense · 2014 - 2022

View All Grants

Education, Training & Certifications

The University of Chicago · 1987 M.D.
University of California, Berkeley · 1984 M.A.